{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:19:26Z","timestamp":1777418366537,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate the relationship between baseline seizure frequency and stabilized topiramate dosage and the effect of individualized treatment on tolerability in adults with partial-onset seizures receiving other antiepileptic drugs (AEDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>In this 20-week, open-label trial, dosages of medications were adjusted according to clinical response. Dosage and seizure response data were analyzed for 2 groups defined by baseline seizure frequency: &lt;4 and \u22654 seizures per month.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>In the outcome evaluable population (n = 471), the mean \u00b1 SEM stable topiramate dosage was 303 \u00b1 139 mg\/d when baseline seizure frequency was &lt;4 seizures\/month and 341 \u00b1 153 mg\/d when baseline seizure frequency was \u22654 seizures\/month (p = 0.005). The most common adverse events were somnolence (8.5%), fatigue (7.3%), nausea (5.3%), and dizziness (5.0%). Cognitive complaints were reported by &lt;3% of patients. When concomitant AED dosages were reduced, 14% of patients discontinued topiramate due to adverse events compared with 23% if the concomitant AED dosage was unchanged or increased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>When clinicians individualize topiramate dosage according to clinical response, the stabilized topiramate dosage as add-on therapy is influenced by baseline seizure frequency. Topiramate tolerability is improved when dosages of concomitant AEDs are reduced.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1c133","type":"journal-article","created":{"date-parts":[[2003,4,22]],"date-time":"2003-04-22T17:04:35Z","timestamp":1051031075000},"page":"615-620","source":"Crossref","is-referenced-by-count":20,"title":["Topiramate Titration to Response: Analysis of Individualized Therapy Study (TRAITS)"],"prefix":"10.1177","volume":"37","author":[{"given":"W Edwin","family":"Dodson","sequence":"first","affiliation":[{"name":"W Edwin Dodson MD, Professor of Pediatrics and Neurology, Department of Pediatric Neurology, School of Medicine, Washington University, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Kamin","sequence":"additional","affiliation":[{"name":"Marc Kamin MD, Executive Director, Clinical Investigations, Clinical Affairs, Ortho\u2013McNeil Pharmaceutical, Raritan, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Kraut","sequence":"additional","affiliation":[{"name":"Lesley Kraut MBA, Assistant Director, CNS Projects, Clinical Affairs, Ortho\u2013McNeil Pharmaceutical"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H","family":"Olson","sequence":"additional","affiliation":[{"name":"William H Olson PhD, Senior Director, Quantitative Methodology, Ortho\u2013McNeil Pharmaceutical"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Chen","family":"Wu","sequence":"additional","affiliation":[{"name":"Shu-Chen Wu PhD, Assistant Director, Quantitative Methodology, Ortho\u2013McNeil Pharmaceutical"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,5,1]]},"reference":[{"key":"bibr1-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)00029-0"},{"key":"bibr2-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00606.x"},{"key":"bibr3-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00649.x"},{"key":"bibr4-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1684"},{"key":"bibr5-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1678"},{"key":"bibr6-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2002.02071.x"},{"key":"bibr7-aph.1C133","volume-title":"Product information. Topamax (topiramate)","year":"1996"},{"key":"bibr8-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"bibr9-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00282.x"},{"key":"bibr10-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02175.x"},{"key":"bibr11-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10093"},{"issue":"3","key":"bibr12-aph.1C133","first-page":"60","volume":"38","author":"Alapati A","year":"1999","journal-title":"Epilepsia"},{"key":"bibr13-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00165.x"},{"key":"bibr14-aph.1C133","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.6.759"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1C133","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:06:59Z","timestamp":1777374419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1C133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1345\/aph.1C133"],"URL":"https:\/\/doi.org\/10.1345\/aph.1c133","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}